Who makes Medium Dose GRT6005?

Medium Dose GRT6005 is developed by Tris Pharma, Inc..

What development phase is Medium Dose GRT6005 in?

Medium Dose GRT6005 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Medium Dose GRT6005

Tris Pharma, Inc. · Phase 2 active Small molecule

At a glance

Generic name	Medium Dose GRT6005
Sponsor	Tris Pharma, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain. (PHASE2)
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Medium Dose GRT6005 CI brief — competitive landscape report
Medium Dose GRT6005 updates RSS · CI watch RSS
Tris Pharma, Inc. portfolio CI